A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood‐retinal barrier in diabetes
Authors:
Open Access
- 16 June 2008
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 22 (9) , 3310-3317
Abstract
One of the major complications of diabetes is the alteration of the blood‐retinal barrier, leading to retinal edema and consequent vision loss. The aim of this study was to evaluate the role of the urokinase plasminogen activator (uPA)/uPA receptor (uPAR) system in the regulation of retinal vascular permeability. Biochemical, molecular, and histological techniques were used to examine the role of uPA and uPAR in the regulation of retinal vascular permeability in diabetic rats and cultured retinal endothelial cells. The increased retinal vascular permeability in diabetic rats was associated with a decrease in vascular endothelial (VE)‐cadherin expression in retinal vessels. Treatment with the uPA/uPAR‐inhibiting peptide (Å6) was shown to reduce diabetes‐induced permeability and the loss of VE‐cadherin. The increased permeability of cultured cells in response to advanced glycation end products (AGEs) was significantly inhibited with Å6. Treatment of endothelial cells with specific matrix metalloproteinases or AGEs resulted in loss of VE‐cadherin from the cell surface, which could be inhibited by Å6. uPA/uPAR physically interacts with AGEs/receptor for advanced glycation end products on the cell surface and regulates its activity. uPA and its receptor uPAR play important roles in the alteration of the blood‐retinal barrier through proteolytic degradation of VE‐cadherin. The ability of Å6 to block retinal vascular permeability in diabetes suggests a potential therapeutic approach for the treatment of diabetic macular edema.—Navaratna, D., Menicucci, G., Maestas, J., Srinivasan, R., McGuire, P., Das, A. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood‐retinal barrier in diabetes. FASEB J. 22, 3310–3317 (2008)Keywords
Funding Information
- Juvenile Diabetes Research Foundation International (1–2006–36)
- National Institutes of Health (RO1 EY12604)
This publication has 38 references indexed in Scilit:
- Proteolytic Degradation of VE-Cadherin Alters the Blood-Retinal Barrier in DiabetesDiabetes, 2007
- uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s viewThrombosis and Haemostasis, 2007
- VEGF Activation of Protein Kinase C Stimulates Occludin Phosphorylation and Contributes to Endothelial PermeabilityInvestigative Ophthalmology & Visual Science, 2006
- Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and αvβ5 integrinJournal of Cell Science, 2006
- The urokinase plasminogen activator and its receptorThrombosis and Haemostasis, 2005
- Cooperativity between the Ras-ERK and Rho-Rho Kinase Pathways in Urokinase-type Plasminogen Activator-stimulated Cell MigrationJournal of Biological Chemistry, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathyBritish Journal of Ophthalmology, 2000
- Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling PathwaysJournal of Biological Chemistry, 1999
- The Wisconsin epidemiologic study of diabetic retinopathy: XVIIOphthalmology, 1998